|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0021051,
umls-concept:C0030705,
umls-concept:C0032952,
umls-concept:C0036043,
umls-concept:C0042679,
umls-concept:C0079744,
umls-concept:C0085752,
umls-concept:C0086418,
umls-concept:C0282460,
umls-concept:C0393022,
umls-concept:C1274040
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-1-25
|
|
pubmed:abstractText |
Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma. This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact. Patients were eligible if they had performance status <3 and absence of active opportunistic infections. Eighty-one patients were enrolled, 57 in stages III or IV, International Prognostic Index (IPI) 0 or 1 (n = 26), 2 (n = 19), 3 (n = 20) and 4 or 5 (n = 16), and median CD4 lymphocyte count of 0.158 x 10(9)/l. The main adverse events were neutropenia (48% of cycles) and infections (10% of cycles), which were fatal in seven patients. Complete response was achieved in 55 (69%) patients, with an estimated 3-year disease-free survival of 77% and 3-year overall survival of 56%. IPI score and virological response to HAART were the prognostic parameters for response and survival. In HIV-related DLBCL R-CHOP is feasible, safe and effective. The prognosis depends on lymphoma-related parameters and on the response to HAART.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1365-2141
|
|
pubmed:author |
pubmed-author:AbellaEugeniaE,
pubmed-author:GarcíaMartaM,
pubmed-author:GardellaSantiagoS,
pubmed-author:González-BarcaEvaE,
pubmed-author:López-GuillermoArmandoA,
pubmed-author:LópezAndresA,
pubmed-author:MirallesPilarP,
pubmed-author:MorgadesMireiaM,
pubmed-author:OriolAlbertA,
pubmed-author:PETHEMA, GELTAMO, GELCAB and GESIDA Groups,
pubmed-author:RiberaJosep-MariaJM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
140
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
411-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18162120-Adult,
pubmed-meshheading:18162120-Aged,
pubmed-meshheading:18162120-Antibodies, Monoclonal,
pubmed-meshheading:18162120-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18162120-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18162120-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:18162120-CD4 Lymphocyte Count,
pubmed-meshheading:18162120-Cyclophosphamide,
pubmed-meshheading:18162120-Doxorubicin,
pubmed-meshheading:18162120-Female,
pubmed-meshheading:18162120-Humans,
pubmed-meshheading:18162120-Lymphoma, AIDS-Related,
pubmed-meshheading:18162120-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:18162120-Male,
pubmed-meshheading:18162120-Middle Aged,
pubmed-meshheading:18162120-Neoplasm Staging,
pubmed-meshheading:18162120-Prednisone,
pubmed-meshheading:18162120-Prognosis,
pubmed-meshheading:18162120-Survival Analysis,
pubmed-meshheading:18162120-Treatment Outcome,
pubmed-meshheading:18162120-Vincristine,
pubmed-meshheading:18162120-Viral Load
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
|
|
pubmed:affiliation |
Haematology Department, Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Spain. jribera@iconcologia.net
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
